74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Akebia Therapeutics Inc
Closed
SectorHealthcare
2.27 5.09
Overview
Share price change
24h
Min
2.15
Max
2.27
Income | -2.8M -23M |
|---|---|
Sales | 9.1M 46M |
EPS | -0.1 |
Profit margin | -49.044 |
Employees | 181 |
EBITDA | -2.6M -6.6M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +185.09% upside |
Next Earnings | 8 May 2025 |
|---|
Market Cap | 128M 541M |
|---|---|
Previous open | -2.82 |
Previous close | 2.27 |
Technical Score
By Trading Central
Confidence
Strong Bullish Evidence
Akebia Therapeutics Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Akebia Therapeutics Inc Forecast
Price Target
By TipRanks
185.09% upside
12 Months Forecast
Average 6.5 USD 185.09%
High 7.5 USD
Low 6 USD
Based on 3 Wall Street analysts offering 12 month price targets forAkebia Therapeutics Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Akebia Therapeutics Inc
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
